1/15
10:00 am
ino
*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Low
Report
*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
1/13
04:16 pm
ino
*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Low
Report
*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
1/10
09:39 am
ino
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 [Seeking Alpha]
Low
Report
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 [Seeking Alpha]
1/8
10:00 am
ino
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
1/6
12:45 pm
ino
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
12/30
04:25 pm
ino
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
12/30
11:07 am
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/30
08:12 am
ino
Inovio announces U.S. FDA accepted BLA for INO-3107 [Yahoo! Finance]
Low
Report
Inovio announces U.S. FDA accepted BLA for INO-3107 [Yahoo! Finance]
12/29
11:27 am
ino
Inovio Pharmaceuticals Says FDA Accepts Biologics License Application for INO-3107 for Standard Review; Shares Fall [Yahoo! Finance]
Neutral
Report
Inovio Pharmaceuticals Says FDA Accepts Biologics License Application for INO-3107 for Standard Review; Shares Fall [Yahoo! Finance]
12/29
08:05 am
ino
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
High
Report
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
12/19
04:05 pm
ino
INOVIO Reports Inducement Grant Under Inducement Plan
Low
Report
INOVIO Reports Inducement Grant Under Inducement Plan
12/16
04:37 pm
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:09 pm
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:05 am
ino
INOVIO to Participate in December Investor Conferences
Medium
Report
INOVIO to Participate in December Investor Conferences
11/14
07:08 pm
ino
Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines [Yahoo! Finance]
Medium
Report
Individual investors invested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) lost 13% last week, institutions remained on the sidelines [Yahoo! Finance]
11/14
09:05 am
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
11/14
09:05 am
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
11/12
09:56 am
ino
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress [Seeking Alpha]
Medium
Report
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress [Seeking Alpha]
11/11
08:40 am
ino
INOVIO Announces Pricing of $25 Million Public Offering
Low
Report
INOVIO Announces Pricing of $25 Million Public Offering
11/11
12:30 am
ino
Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/10
06:09 pm
ino
INOVIO Announces Proposed Public Offering
Medium
Report
INOVIO Announces Proposed Public Offering
11/10
04:05 pm
ino
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Medium
Report
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/10
10:01 am
ino
Here are the major earnings after the close Monday [Seeking Alpha]
Low
Report
Here are the major earnings after the close Monday [Seeking Alpha]
11/4
07:21 am
ino
Inovio Pharmaceuticals (NASDAQ:INO) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Inovio Pharmaceuticals (NASDAQ:INO) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
08:05 am
ino
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
Medium
Report
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults